Supriya Lifescience Limited (BOM:543434)

Market Cap	76.29B +33.6%
Revenue (ttm)	8.28B +18.9%
Net Income	2.09B +11.3%
EPS	25.98 +11.3%
Shares Out	n/a
PE Ratio	36.48
Forward PE	n/a
Dividend	1.00 (0.12%)
Ex-Dividend Date	Sep 4, 2025

Volume	37,352
Open	901.45
Previous Close	901.75
Day's Range	896.90 - 957.95
52-Week Range	545.65 - 1,085.50
Beta	n/a
Analysts	Buy
Price Target	940.00 (-1.28%)
Earnings Date	May 27, 2026

About Supriya Lifescience

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, ...

• Industry: Pharmaceutical Preparations
• Founded: 1987
• Employees: 515
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543434

Financial Performance

In fiscal year 2026, Supriya Lifescience's revenue was 8.28 billion, an increase of 18.86% compared to the previous year's 6.96 billion. Earnings were 2.09 billion, an increase of 11.26%.

Analyst Summary

According to 2 analysts, the average rating for 543434 stock is "Buy." The 12-month stock price target is ₹940.00, which is a decrease of -1.28% from the latest price.

Price Target

₹940.00

(-1.28% downside)

Analyst Consensus: Buy